Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

Table 4

Summary of suspected adverse drug reactions (SADRs) recorded during the study.

	No. of events	No. of patients (%)
All SADRs	195	132 (2.2%)
SADRs considered related; to study treatment	151	97 (1.6%)
SADRs leading to study termination	93	62 (1.1%)
Severe SADRs	15	10 (0.2%)
Serious SADRs	12	6 (0.1%)